Jpmorgan Chase & CO Eledon Pharmaceuticals, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ELDN
# of Institutions
34Shares Held
18.3MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA6.29MShares$31.2 Million0.51% of portfolio
-
Armistice Capital, LLC New York, NY2.34MShares$11.6 Million0.08% of portfolio
-
Zimmer Partners, LP New York, NY2.11MShares$10.5 Million0.11% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY1.5MShares$7.44 Million0.03% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.3MShares$6.43 Million0.5% of portfolio
About Eledon Pharmaceuticals, Inc.
- Ticker ELDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,756,800
- Market Cap $68.2M
- Description
- Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...